	SINUS RHYTHM (n=745)	ATRIAL FIBRILLATION (n=653)	Total (n=1398)	P value
Age (mean±SD)	72 ± 12	72 ±12	72±12	0.980
Female, n (%)	299 (40.1)	295 (45.2)	594 (42.4)	0.053
Active smokers, n (%)	100 (13.4)	51 (7.8%)	151 (10.8)	<0.001
Alcohol consumption, n (%)	88 (11.8)	65(9.9)	153 (10.9)	0.227
Hypertension, n (%)	564 (75.7)	522 (79.9)	1086 (77.6)	0.052
Diabetes mellitus, n (%)	376 (50.4)	279 (42.7)	655 (46.8)	0.003
Hyperlipidemia, n (%)	414 (55.5)	355 (54.3)	769 (55.0)	0.718
Coronary artery disease, n (%)	222 (29.7)	150 (23.2)	372 (26.6)	0.004
Previous PCI, n (%)	141 (18.6)	84 (12.8)	225 (16.0)	0.009
Previous CABG, n (%)	46 (6.1)	35(5.3)	81 (5.7)	0.010
Previous stroke, n (%)	67 (8.9)	68 (10.4)	135 (9.6)	0.331
Peripherical artery disease, n (%)	82 (11.0)	69 (10.5)	151 (10.8)	0.666
COPD, n (%)	101 (13.5)	110 (16.8)	211 (15.0)	0.088
Previous HF, n (%)	403 (54.0)	374 (57.2)	777 (55.5)	0.273
Ischemic HF aetiology, n (%)	305 (40.9)	170 (26.0)	475 (34.0)	<0.01
Previous biventricular pacing	8(1.0)	13(1.9)	21 (1.5)	0.008
Previous defibrilator	45(5.5)	34 (4.9)	79(5.6)	0.1000
Previous pacemaker	16(2.0)	15(2.2)	31(2.2)	0.125
Left ventricular ejection fraction (mean±SD)	43 ±18	46 ± 16	45 ±17	0.004

Body mas index, Kg/m2 (mean±SD)	28±5	29±6	29 ±6	0.048
Systolic blood pressure at admission, mmHg (mean±SD)	137±30	133±26	135 ±29	0.009
Admission HR, bpm (mean±SD)	85±22	96±28	90 ±26	<0.001
Discharge HR, bpm (mean±SD)	72±13	74±15	73±14	0.032
HRD, bpm (mean±SD)	12 ±23	21±30	17±27	<0.001
QRS duration, msec (mean±SD)	110±30	108±29	110±30	0.249
Hemoglobine, levels g/L (mean±SD)	12 ±2	12 ±2	12 ±2	0.669
Sodium, mmeq/lm (mean±SD)	138±4	139±4	138±4	0.477
Creatinine, g/dl (mean±SD)	1.1±0.2	1.1±0.5	1.12±0.6	0.049
NT- ProBNP. pg/ml(mean±SD)	847±1267	744±855	798±1000	0.139
Beta-blockers at discharge, n (%)	535 (71.8)	476 (72.8)	1011(72.3)	0.746
ACEIs at discharge, n (%)	425 (57.0)	310 (47.4)	735 (52.5)	<0.001
ARBs at discharge, n (%)	135(18.1)	130 (19.9)	265 (18.9)	0.392
Statins at discharge, n (%)	493 (66.1)	328 (50.2)	821 (58.7)	<0.001
MRAs at discharge, n (%)	346 (46.4)	271 (41.5)	617 (44.1)	0.001
Digoxin at discharge, n (%)	36 (4.8)	216 (33.0)	252 (18.0)	<0.001
Diuretics at discharge, n (%)	621(83.3)	567 (86.8)	1188 (84.9)	0.090
Calcium Channel blockers at discharge, n,(%)	17(2.2)	31 (4.7)	48 (3.4)	0.035
Amiodarone at discharge, n (%)	73 (9.7)	72(11.0)	150(10.3)	0.654

Suplemmentary Table 1. Baseline characteristics in whole population according to the presence of sinus rhythm or atrial fibrillation.

ACEIs: angiotensin converting enzyme inhibitors; ARBs: angiotensin II-receptor blockers; CABG: coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; HF; heart failure; HR; heart rate; HRD; heart rate difference; MRAs: mineralocortoid receptor antagonists, NT-proBNP: NT-proBrainNatriuretic Peptide; PCI: percutaneous coronary intervention; SD: standard desviation

	Q1 (HR 38-64 bpm) (n=170)	Q2 (HR 64-73 bpm) (n=160)	Q3 HR (73-84 bpm) (n=166)	Q4 (HR 84-140 bpm) (n=157)	P value
Age (mean±SD)	73 ±11	71 ±12	71 ±12	72 ±11	0.623
Female, n (%)	69 (40.6)	70 (43.8)	76 (45.8)	80 (51.0)	0.294
Active smokers, n (%)	16 (9.4)	13 (8.1)	11 (6.6)	11(7.0)	0.848
Alcohol consumption, n (%)	16(9.4)	13(8.1)	21(12.7)	15 (9.6)	0.575
Hypertension, n (%)	138 (81.1)	124 (77.5)	136(81.9)	124(79.0)	0.807
Diabetes mellitus, n (%)	62 (36.4)	69 (43.1)	73 (44.0)	75 (47.8)	0.234
Hyperlipidemia, n (%)	97 (57.0)	88 (55.0)	85 (51.2)	85 (54.1)	0.684
Coronary artery disease, n (%)	39 (22.9)	27 (16.8)	43 (25.9)	41 (26.1)	0.151
Previous PCI, n (%)	23 (13.5)	14(8.7)	24(14.4)	23(14.6)	0.878
Previous CABG, n (%)	9(5.2)	10(6.2)	8(4.8)	8(5.1)	0.863
Previous stroke, n (%)	16(9.4)	17(10.6)	20 (12.0)	135 (9.5)	0.843
Peripherical artery disease, n (%)	24 (14.1)	7(5.3)	19 (11.4)	19 (12.1)	0.024
COPD, n (%)	29(17.0)	28(17.5)	23 (13.8)	30 (19.1)	0.678
Previous HF, n (%)	93(54.7)	105(65.6)	97(58.4)	79 (50.3)	0.043
Ischemic HF aetiology, n (%)	44(25.8)	40(25.0)	46(27.7)	40(25.4)	0.110
Left ventricular ejection fraction (mean±SD)	47± 17	46 ± 17	45± 17	48± 15	0.526
Body mas index, Kg/m2 (mean±SD)	28±5	29±5	30±6	30±6	0.108

Systolic blood pressure at admission, mmHg (mean±SD)	137±27	131±26	130±24	132±25	0.102
Admission HR, bpm (mean±SD)	93±32	93±27	95±28	100±24	0.069
Discharge HR, bpm (mean±SD)	56±5	67±2	76±3	91±8	<0.001
HRD, bpm (mean±SD)	37 ±32	26 ±28	18 ±28	9±24	<0.001
QRS duration, msec (mean±SD)	117±33	109±28	107±26	102±26	<0.001
Hemoglobine, levels g/L (mean±SD)	12 ±1	12 ±2	12 ±2	12 ±2	0.217
Sodium, mmeq/lm (mean±SD)	139±4	138±4	138±4	139±4	0.052
Creatinine, g/dl (mean±SD)	1.0±0.4	1.1±0.5	1.0±0.5	1.1±0.7	0.896
NT- ProBNP. pg/ml(mean±SD)	738±824	752±998	728±762	760±850	0.992
Beta-blockers at discharge, n (%)	115(65.6)	117(73.1)	128(77.1)	116(73.9)	0.256
ACEIs at discharge, n (%)	95(55.9)	80(50.0)	66(39.7)	69(43.7)	0.023
ARBs at discharge, n (%)	29 (17.0)	33(20.6)	40 (24.0)	28 (17.8)	0.349
Statins at discharge, n (%)	93(54.7)	81(50.6)	82(49.3)	72(45.8)	0.459
MRAs at discharge, n (%)	70(41.1)	74(46.2)	62 (37.3)	65 (41.4)	0.720
Digoxin at discharge, n (%)	39(22.9)	56(35.0)	55(34.4)	66(42.0)	0.003
Diuretics at discharge, n (%)	148 (87.1)	134(83.7)	151(90.9)	134(85.3)	0.281
Calcium Channel blockers at discharge, n (%)	3(1.7)	5(3.1)	10(6.0)	13 (8.2)	0.037
Amiodarone at discharge, n (%)	26(15.2)	16(10.3)	11(6.6)	15 (9.5)	0.073

Suplemmentary Table 3. Baseline characteristic in atrial fibrillation patients according to discharge heart rate

ACEIs: angiotensin converting enzyme inhibitors; ARBs: angiotensin II-receptor blockers; CABG: coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; HF; heart failure; HR; heart rate; HRD; heart rate difference; MRAs: mineralocortoid receptor antagonists, NT-proBNP: NT-proBrainNatriuretic Peptide; PCI: percutaneous coronary intervention; SD: standard desviation

	SINUS RHYTHM (n=153)	ATRIAL FIBRILLATION (n=145)	Total (n=298)	P value
Age (mean±SD)	72 ± 12	72 ±12	72±12	0.980
Female, n (%)	62(40.5)	65 (44.8)	127 (42.6)	0.453
Active smokers, n (%)	14 (9.2)	5(3.4)	19 (6.4)	0.126
Alcohol consumption, n (%)	15 (9.9)	11(7.6)	26(8.8)	0.487
Hypertension, n (%)	124 (81.0)	119(82.1)	243 (81.5)	0.820
Diabetes mellitus, n (%)	85 (55.9)	78 (53.8)	163 (54.9)	0.713
Hyperlipidemia, n (%)	81 (52.9)	81 (56.6)	162 (54.7)	0.523
Coronary artery disease, n (%)	57(38.3)	44 (31.4)	101(34.9)	0.224
Previous PCI, n (%)	26 (16.9)	23 (16.0)	49 (16.7)	0.630
Previous CABG, n (%)	13 (8.7)	13(9.0)	26 (8.8)	0.987
Previous stroke, n (%)	21 (14.0)	26 (12.8)	47 (16.0)	0.330
Peripherical artery disease, n (%)	27 (18.1)	19(13.4)	46 (15.8)	0.268
COPD, n (%)	23 (15.3)	29 (20.3)	52 (17.7)	0268
Previous HF, n (%)	99(64.7)	94 (65.3)	193 (65.0)	0.918
Ischemic HF aetiology, n (%)	72 (51.1)	48 (37.2)	120 (44.4)	0.289
Left ventricular ejection fraction (mean±SD)	43 ±16	46 ± 17	44±17	0.228
Body mas index, Kg/m2 (mean±SD)	28±4	28±5	28±6	0.747
Systolic blood pressure at admission, mmHg (mean±SD)	131±28	126±24	129 ±26	0.102

Admission HR, bpm (mean±SD)	85±21	90±25	87±23	0.085
Discharge HR, bpm (mean±SD)	74±14	77±16	76±15	0.107
HRD, bpm (mean±SD)	9±22	13±28	11±25	0.264
QRS duration, msec (mean±SD)	113±31	118±33	115±32	0.248
Hemoglobine, levels g/L (mean±SD)	11±2	11 ±2	11 ±2	0.713
Sodium, mmeq/lm (mean±SD)	137±5	137±5	137±5	0.694
Creatinine, g/dl (mean±SD)	1.4±0.9	1.3±0.6	1.4±0.7	0.409
NT- ProBNP. pg/ml(mean±SD)	1400±1832	1148±1132	1269±1511	0.228
Beta-blockers at discharge, n (%)	83(54.2)	82(56.5)	165(55.3)	0.716
ACEIs at discharge, n (%)	61(39.8)	46 (31.7))	107(35.9)	0.432
ARBs at discharge, n (%)	19(12.4)	16(11.0)	35 (11.7)	0.552
Statins at discharge, n (%)	86 (56.2)	62 (42.7)	148 (49.6)	0.002
MRAs at discharge, n (%)	54(35.2)	53(36.5)	107 (35.9)	0.735
Digoxin at discharge, n (%)	10 (6.5)	44(30.5)	54 (18.1)	<0.001
Diuretics at discharge, n (%)	116(75.8)	116(80.0)	232 (77.8)	0.871
Calcium Channel blockers at discharge, n,(%)	5(3.2)	3 (2.0)	8 (2.6)	0.452
Amiodarone at discharge, n (%)	17(11.1)	12 (8.2)	29 (9.7)	0.303

Suplemmentary Table 4. Baseline characteristics in all cause mortality population according to the presence of sinus rhythm or atrial fibrillation.

ACEIs: angiotensin converting enzyme inhibitors; ARBs: angiotensin II-receptor blockers; CABG: coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; HF; heart failure; HR; heart rate; HRD; heart rate difference; MRAs: mineralocortoid receptor antagonists, NT-proBNP: NT-proBrainNatriuretic Peptide; PCI: percutaneous coronary intervention; SD: standard desviation

	Q1 (HR 40-63 bpm) (n=189)	Q2 HR (63-70 bpm) (n=188)	Q3 HR (70-80 bpm) (n=200)	Q24 (HR 80-127 bpm) (n=168)	P value
Age (mean±SD)	72 ±11	73 ±12	72 ±11	72 ±12	0.879
Female, n (%)	62 (32.8)	79 (42.0)	82 (41.0)	76 (45.2)	0.094
Active smokers, n (%)	31 (16.4)	25 (13.2)	28 (14.0)	21(12.5)	0.770
Alcohol consumption, n (%)	19 (10.0)	25(13.2)	24(12.0)	20 (11.9)	0.779
Hypertension, n (%)	146 (77.2)	146 (77.6)	147(73.5)	125(74.4)	0.768
Diabetes mellitus, n (%)	87 (46.0)	99 (52.6)	101 (50.5)	89 (52.9)	0.583
Hyperlipidemia, n (%)	115 (60.8)	98 (52.1)	113 (56.5)	88 (52.3)	0.254
Coronary artery disease, n (%)	59 (31.2)	58 (30.8)	55 (27.5)	50 (29.7)	0.877
Previous PCI, n (%)	38 (20.1)	36(19.1)	37(18.5)	30(17.8)	0.268
Previous CABG, n (%)	13(6.8)	10(5.3)	13(6.5)	10(5.9)	0.302
Previous stroke, n (%)	24(12.6)	13(6.9)	17 (8.5)	13 (7.7)	0.204
Peripherical artery disease, n (%)	26 (13.7)	23(12.2)	14 (7.0)	19 (11.3)	0.169
COPD, n (%)	28(14.8)	18(9.5)	36 (18.0)	19 (11.3)	0.073
Previous HF, n (%)	104(55.0)	112(59.5)	105(52.5)	82(48.8)	0.179
Ischemic HF aetiology, n (%)	82(43.3)	82(43.6)	81(40.5)	60(35.7)	0.144
Left ventricular ejection fraction (mean±SD)	44± 16	46 ± 18	42± 18	41± 18	0.041
Body mas index, Kg/m2 (mean±SD)	28±5	28±6	29±6	29±5	0.489
Systolic blood pressure at admission, mmHg	138±33	139±29	136±28	133±31	0.164

Admission HR, bpm (mean±SD)	78±22	81±20	88±24	92±18	<0.001
HRD, bpm (mean±SD)	21 ±22	14 ±20	12 ±24	1±20	<0.001
QRS duration, msec (mean±SD)	113±30	113±30	109±29	107±31	0.248
Hemoglobine, levels g/L (mean±SD)	12 ±2	12 ±2	12 ±2	12 ±2	0.225
Sodium, mmeq/lm (mean±SD)	138±3	138±4	139±4	138±4	0.337
Creatinine, g/dl (mean±SD)	1.1±0.57	1.0±0.5	1.0±0.5	1.1±0.7	0.435
NT- ProBNP. pg/ml(mean±SD)	796±1111	748±916	956±1570	893±1380	0.529
Beta-blockers at discharge, n (%)	144(76.1)	140(74.4)	139(69.5)	112(66.6)	0.157
ACEIs at discharge, n (%)	116(61.3)	103(54.4)	114(57.0)	92(54.7)	0.600
ARBs at discharge, n (%)	32(16.9)	45(23.9)	31(15.5)	27(16.0)	0.121
Statins at discharge, n (%)	142(75.1)	116(61.8)	137(68.5)	98(58.3)	0.007
MRAs at discharge, n (%)	79 (41.7)	80 (42.5)	100 (50.0)	87 (51.7)	0.201
Digoxin at discharge, n (%)	7(3.7)	8(4.2)	9(4.5)	12(7.1)	0.395
Diuretics at discharge, n (%)	144 (76.1)	164(87.2)	168(84.0)	145(86.3)	0.029
Calcium Channel blockers at discharge, n (%)	2(1.0)	4(2.1)	7(3.5)	4 (2.3)	0.674
Amiodarone at discharge, n (%)	24(13.0)	24(13.3)	14(7.2)	11 (6.8)	0.057

Suplemmentary Table 2. Baseline characteristic in sinus rhythm patients according to discharge heart rate

ACEIs: angiotensin converting enzyme inhibitors; ARBs: angiotensin II-receptor blockers; CABG: coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; HF; heart failure; HR; heart rate; HRD; heart rate difference; MRAs: mineralocortoid receptor antagonists, NT-proBNP: NT-proBrainNatriuretic Peptide; PCI: percutaneous coronary intervention; SD: standard desviation

Suplementary table 5. Significant multivariate predictors of cardiovascular outcomes in sinus rhythm patients

All cause one year mortality	OR, CI 95%
Age	1.04 (1.02-1.06)
SBP	0.99 (0.98,0.99)
Creatinine	1.33 (1.00-1.76)
Sodium	0.96 (0.91-0.99)
NT-proBNP (log10)	1.99 (1.17-5.04)

Cardiovascular one- year mortality	OR, CI 95%
Age	1.03 (1.01-1.05)
Betablockers	0.51 (0.31-0.86)
SBP	0.98 (0.97- 0.99)
Sodium	0.94 (0.89-0.99)
NT-proBNP (log10)	2.23 (1.28-3.88)

One year HF readmission	OR, CI 95%
Previous HF admission	2.14(1.54-2.98)

CI: confidence interval; HF: heart failure; NT-proBNP: NT-proBrain Natriuretic Peptide; OR: odds ratio; RR: relative risk; SBP: systolic blood pressure at admission

Suplementary table 6. Significant multivariate predictors of cardiovascular outcomes in atrial fibrillation patients.

All cause one year mortality	OR, CI 95%
Age	1.03 (1.00-1.06)
Creatinine	1.66 (1.12-2.47)
Hemoglobine	0.98 (0.97-0.99)
NT-proBNP (log10)	3.31 (1.90-5.75)
Diabetes mellitus	1.68 (1.09-2.57)
Betablockers	0.51 (0.32- 0.80)

Cardiovascular one- year mortality	OR, CI 95%
Age	1.03 (1.00-1.07)
Betablockers	0.51 (0.30-0.86)
Hemoglobine	0.98 (0.97- 0.99)
Sodium	0.94 (0.89-0.99)
NT-proBNP (log10)	2.50 (1.33-4.71)

One year HF readmission	OR, CI 95%
Age	1.03 (1.00-1.05)
Creatinine	1.77 (1.25-2.52)
Hemoglobine	0.98 (0.97-0.99)

CI: confidence interval; HF: heart failure; NT-proBNP: NT-proBrain Natriuretic Peptide; OR: odds ratio; RR: relative risk; SBP: systolic blood pressure at admission